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PURPOSE. Matrix metalloproteinases (MMPs) comprise a family of zinc-dependent endopep-
tidases involved in wound healing processes, including neovascularization and fibrosis. We
assessed MMP protein expression levels in diseased corneas of patients requiring penetrating
and deep anterior lamellar keratoplasty. The purpose of this study was to test the hypothesis
that upregulation of MMPs in diseased corneas is positively associated with clinical levels of
corneal neovascularization and fibrosis.
METHODS. Protein expression levels of nine individual MMPs were quantified simultaneously in
human corneal lysates by using the Bio-Plex Pro Human MMP 9-Plex Panel and the MAGPIX
technology. Measurements of MMP1, MMP2, MMP3, MMP7, MMP8, MMP9, MMP10, MMP12,
and MMP13 were performed on diseased specimens from 21 patients undergoing corneal
transplantation (17 for penetrating keratoplasty and 4 for deep anterior lamellar keratoplasty)
and 6 normal control corneas.
RESULTS. Luminex-based expression analysis revealed a significant overexpression of four of
the nine MMPs tested (MMP2, MMP8, MMP12, and MMP13) in patient samples compared to
control. Significant overexpression of MMP1, MMP2, MMP8, MMP12, and MMP13 was
observed in diseased corneas with neovascularization compared with diseased corneas
without neovascularization. Overexpression of MMP1, MMP2, MMP8, MMP12, and MMP13
also corresponded with the levels of corneal fibrosis. Finally, reduced expression of MMP3
was detected in keratoconus patients.
CONCLUSIONS. Multiple MMPs are expressed in the corneas of patients with chronic disease
requiring keratoplasty even when the pathologic process appears to be clinically inactive. In
particular, the expression of several MMPs (MMP2, MMP8, MMP12, and MMP13) is positively
associated with increased levels corneal fibrosis and neovascularization.
Keywords: cornea, matrix metalloproteinases, penetrating keratoplasty, deep anterior lamellar
keratoplasty
Matrix metalloproteinases (MMPs) comprise a family of zinc-dependent endopeptidases involved in extracellular ma-
trix (ECM) remodeling during development or following
disease or injury.1–3 Extensive ECM remodeling processes
occur during wound healing, including neovascularization
and fibrosis. MMP substrates4 encompass a large variety of
ECM components involved in maintaining healthy tissue2 and
repairing diseased tissue.5 Individual MMPs have been de-
scribed to have either a protective or destructive effect in
animal and in vitro models of organ injury, including the eye.6
Although MMPs have been found to be expressed in all eye
tissues,7 our understanding of their individual roles in vivo
continues to evolve.8,9
Because the cornea is the outermost layer of the eye, it is
prone to injury and infections that may lead to scarring and loss
of clarity.10 Once vision is compromised from corneal
opacification, few nonsurgical treatment options are available,
and replacement of the diseased cornea with healthy donor
tissue is the standard treatment. Corneal transplantation
techniques have evolved from the traditional full-thickness,
penetrating keratoplasty (PKP) prior to the mid-1990s to the
more recently developed partial-thickness keratoplasty, in
which only the diseased layer or layers are replaced. PKP is
now primarily performed in patients with significant stromal
scarring, extensive corneal distension such as in keratoconus,
and corneal ulceration with or without a history of infection.11
Deep anterior lamellar keratoplasty (DALK) is a partial-
thickness keratoplasty procedure in which the corneal
epithelium and stroma are replaced and the host corneal
endothelium and Descemet’s membrane are left intact.12 A
major advantage of DALK over PKP procedures is the reduced
risk of corneal endothelial cell immune rejection.13
Diseased corneas requiring transplantation may display
increased MMP expression as part of the host response to the
underlying disease process. In other diseased human tissues,
including lung, brain, aorta, and skin, increased MMP expres-
sion and activity has been reported.14–19 Aberrant corneal MMP
expression patterns have been noted in corneas of patients
with diabetes and keratoconus.20,21 Keratoconus, a progressive
corneal degeneration leading to corneal thinning and bulging,
can result in blurred and distorted vision. Although this
disorder has been characterized as noninflammatory due to
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the lack of neovascularization, recent studies have shown the
presence of immune cells in the stroma of keratoconic corneas
and increased cytokine production in keratoconus corneal
cells in vitro.22 Several groups have reported overexpression of
various MMPs in the tear film23–27 or immunostained corneal
tissue28,29 of patients with keratoconus.
The purpose of this study was to test the hypothesis that
upregulation of MMPs in diseased corneas is positively
associated with clinical levels of corneal neovascularization
and fibrosis. We used Luminex technology that allows the
quantification of nine individual MMPs in a single-well,
multiplex format to compare MMP levels in cornea lysates.
MMP protein expression levels were measured in diseased
corneas of patients requiring PKP or DALK and were compared
with levels in healthy donor corneas. We identified the
differential expression of specific MMPs that were positively
associated with clinical findings of corneal fibrosis and
neovascularization and that may serve as biomarkers of these
disease processes.
MATERIALS AND METHODS
Ethical Compliance
Institutional review board/ethics committee approval was
obtained from the University of California, San Francisco
Human Research Protection Program (study number 11-
07020). Informed consent was obtained from all participants.
Protected health information was masked according to Health
Insurance Portability and Accountability Act privacy standards,
and the patient database was managed securely in Research
Electronic Data Capture. All of the described research adhered
to the tenets of the Declaration of Helsinki.
Subjects and Selection Criteria
Corneal samples were collected from all patients (n ¼ 25)
undergoing PKP (n ¼ 20) or DALK (n ¼ 5) by two surgeons
(D.G.H. and J.R.N.) at the University of California, San Francisco
between March 2014 and November 2015. Patient information
(age, sex, affected eye, neovascularization, scarring, and prior
graft) was collected with patient consent from electronic
medical documentation of the clinical examination by using
slit-lamp biomicroscopy from the last visit prior to their
surgery Neovascularization and scarring scores were taken
from the most recent office visit prior to the surgical
procedure. Corneal neovascularization was defined as the
presence of any blood vessel ingrowth into the cornea from
the limbus into previously avascular regions of the cornea.
Superficial neovascularization was defined as vessel ingrowth
into the epithelial and anterior stromal cornea. Deep neovas-
cularization was defined as vessel ingrowth into the posterior
stromal layer of the cornea. Corneal scarring was defined as the
presence of any opacification and lack of corneal clarity.
Scarring density was defined as mild if iris structures could be
observed behind the scar and as dense if iris structures were
obscured by the scar tissue. Clinical notes were also used to
estimate the time for scarring to transplant. Study participants
had no previous consumption of systemic immunomodulatory
medications or medications with known effects on MMP
expression. Age- and sex-matched control eye bank donor
corneas (n ¼ 6) were obtained from the San Diego Eye Bank
from donors who had consented to the use of their corneas for
research purposes. Control samples were processed in the
same manner as the patient samples. Patient samples were
stored at808C on the day of collection, and all samples were
processed simultaneously together as described below.
Sample Preparation and Luminex Assay
Control and diseased corneal samples were thawed on ice,
placed in 400 lL of lysis buffer (Bio-Rad cell lysis kit; Bio-Rad,
Hercules, CA, USA) and sonicated 10 times for 10 seconds.
Lysates were incubated at 48C under gentle agitation for 2
hours. Protein concentration was measured by BCA assay
(Thermo Scientific Pierce, Rockford, IL, USA). Lysates with a
concentration between the range of 0.1 to 1.1 mg/mL were
selected (n ¼ 21; PKP, n ¼ 17; DALK, n ¼ 4) and further
processed using the Bio-Plex Pro Human MMP Panel, 9-Plex
(Bio-Rad) following the manufacturer’s instruction. Briefly,
lysates were incubated with specific anti-MMP antibodies, each
type of which was covalently linked to uniquely colored,
fluorescently labeled magnetic beads. Beads were washed
three times to remove unbound proteins, incubated with a
specific anti-MMP biotinylated detection antibody, washed
again, and incubated with a streptavidin-phycoerythrin conju-
gate serving as a reporter. Fluorescent signals from both the
beads and phycoerythrin were measured in the multiplex
suspension using MAGPIX technology and compared to
standards of known concentrations. Lower limits of detection
for MMP1, 2, 3, 7, 8, 9, 10, 12, and 13 were 35, 450, 116, 5.4,
1.5, 24, 1.6, 1, and 4.9 pg/mL, respectively. Standard curves
were run in duplicate, and all quality control reagents were
within range. Minimal disparity was measured between the
duplicates that all passed the manufacturer’s internal quality
control test before being processed by the calculation
algorithm. Results were analyzed using Bio-Plex Data Analysis
software (Bio-Rad) and the concentration of each individual
MMP per corneal sample was calculated and normalized per
milligram of total protein.
Statistical Analysis
All samples were processed and analyzed in duplicate.
Wilcoxon rank sum tests were used to analyze MMP expression
and clinical variables (sex, age, history of corneal graft, level of
corneal neovascularization, level of corneal fibrosis, and
presence of keratoconus). Fisher’s exact test was used to test
age as a dichotomous variable by using 50 as the age cutoff
because of the small sample size. Spearman correlation
coefficients with bootstrapped 95% confidence intervals were
used to present age as a continuous variable per MMP to assess
if there is any linear correlation. All statistical analyses were
performed using Prism7 (GraphPad Software Inc, La Jolla, CA,
USA). P values less than 0.05 were considered statistically
significant for all analyses.
RESULTS
Eight MMPs Were Consistently Detected and Four
MMPs Were Overexpressed in Diseased Human
Corneal Samples
This study included corneas from 21 patients undergoing PKP
(n¼ 17) or DALK (n¼ 4) and 6 nondiseased control eye bank
corneas (Table 1). Patient and control groups did not differ in
age (P¼0.52, Wilcoxon rank sum test with age as a continuous
variable; P ¼ 0.37, Fisher’s exact test treating age as a
dichotomous variable) or sex (P > 0.99). Patients were
classified based on the presence of neovascularization, amount
of scarring, and history of prior graft or keratoconus (Table 2).
Out of the 21 study participants, 13 (62%) had corneal
neovascularization, 12 (57%) had dense scarring, and 5 (24%)
had mild scarring. Eleven patients (52%) had a history of a prior
corneal graft and four (19%) had a diagnosis of keratoconus.
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Table 2 presents detailed clinical information for the enrolled
patients.
All tested MMPs, except for MMP9, were consistently
detected at various levels in the corneas harvested from
patients undergoing transplantation, indicating that MMP
overexpression was a feature of these diseased corneas (Fig.
1; samples 7–27). Only 2 patient samples and none of the
normal control samples showed concentrations of MMP9
within the measurable range, suggesting that either our assay
was out of range for this specific analyte or that MMP9 is not
expressed in chronic corneal disease. All MMPs except for
MMP3 were expressed at basal levels in control corneas (Fig. 1;
samples 1–6). In contrast, a wide range of MMP expression
levels was observed among patient samples (Fig. 1; samples 7–
27).
The majority of patients had chronic stable disease and
lacked evidence of active inflammation at the time of corneal
transplantation. Despite their disease inactivity, most patients
still expressed a few individual MMPs and had higher MMP
levels compared with the control samples (Fig. 1). This result
indicates that MMPs may still be expressed even when the
pathologic process appears to be clinically inactive.
Patients 8 and 16 had both acute and chronic disease with
evidence of active inflammation at the time of corneal
transplantation. Patient 8 had a history of a recent Salleras
procedure for a chronically painful and irritated eye due to a
failed and edematous PKP graft. The failed corneal graft
resulted in chronic edema, inflammation, and painful epithelial
bullae. The Salleras procedure used corneal cautery to create a
reticular pattern of subepithelial scarring to prevent further
epithelial bullous formation. This cornea, therefore, had
sequelae of both chronic corneal graft failure and scarring as
well as acute active inflammation and neovascularization
induced by therapeutically applied electrocautery. Patient 16
had a history of acute allograft rejection of a previous PKP graft
performed for a prior parasitic (Acanthamoeba) infection,
clinical signs of active and chronic disease processes, and large
vessels in a hazy graft. Interestingly, the acute disease activity
for patients 8 and 16 resulted in an MMP expression profile
that was distinct from the other patients in the cohort and
displayed high levels of all measured MMPs (Fig. 1). This result
indicates that MMPs are highly expressed during active corneal
inflammation and are likely expressed by infiltrating neutro-
phils and macrophages.
Individual MMP expression levels were next compared
between patient and control corneas (Fig. 2). MMP2 (P¼0.04),
MMP8 (P¼ 0.03), MMP12 (P¼ 0.02), and MMP13 (P¼ 0.004)
were significantly overexpressed in corneas of patients
undergoing keratoplasty when compared to controls, whereas
MMP1, MMP3, MMP7, and MMP10 were not. However, we
observed individual variations for each analyte measured.
Various factors could explain a wide range of expression,
including age, sex, previous graft status, presence of neovas-
cularization and scarring, and inflammation levels.
MMP Expression and Patient Sex, Age, and History
of Prior Graft
Because sex has been shown to affect MMP expression levels in
human plasma,30 patients were classified based on sex, and
individual MMP expression levels were compared (Fig. 3A).
There was no significant difference between the two groups
for any MMP, indicating that sex does not have an effect on
MMP expression in diseased corneas (Fig. 3B). Patient age has
also been shown to affect serum MMP levels,31,32 so we
compared MMP expression levels in corneal tissue obtained
from younger (<50 years old) versus older (>50 years old)
patients (Fig. 4A). Out of the eight MMPs studied, only MMP12
was differentially expressed based on this age cutoff with
higher MMP12 expression levels in diseased corneas of
patients over the age of 50 years when compared to younger
patients (Fig. 4B; P ¼ 0.04). We also analyzed age as a
continuous variable per MMP to assess if there is any linear
correlation (Spearman correlation coefficients with boot-
strapped 95% confidence intervals; Fig. 4C). This additional
analysis using age as a continuous variable identified a
significant correlation between MMP2 and MMP3 expression
and age (Fig. 4C). Because tears of patients with corneal graft
failure have been shown to have abnormally high levels of
MMPs,33 we also compared MMP expression levels in corneas
from primary grafts with MMP levels in corneas that were a
regraft from a prior corneal transplant (Fig. 5A). We found that
although levels of seven MMPs were similar between the two
groups, MMP3 was overexpressed in corneal graft failure (Fig.
5B).
MMP Expression and Corneal Neovascularization
We previously found that MMP12 inhibits corneal neovascu-
larization following chemical injury in a mouse model through
altered cleavage of plasminogen and expression of VEGF.34
Other MMPs, including MMP2, MMP9, and MMP14, have been
shown to have an opposite effect on corneal neovasculariza-
tion and promote its development following injury by
regulating VEGF expression.35–38 To examine how MMP
expression corresponds to corneal neovascularization in
patient corneas, MMP expression levels were compared
between control corneas and diseased corneas with or without
neovascularization (Fig. 6). Of the eight MMPs that were
consistently detected, MMP2, MMP8, MMP12, and MMP13
were significantly overexpressed in diseased corneas with
corneal neovascularization as compared to both control
corneas (Fig. 6B; P ¼ 0.005, P ¼ 0.0009, P ¼ 0.0003, and P ¼
0.0003, respectively) and diseased corneas without neovascu-
larization (P ¼ 0.007, P ¼ 0.007, P ¼ 0.01, and P ¼ 0.001,
respectively). MMP1 was significantly overexpressed in cor-
neas with neovascularization when compared to control
corneas (P¼ 0.02). To determine how the acute inflammation
in patients 8 and 16 may be contributing to the MMP
expression levels, we performed a subanalysis that excluded
TABLE 1. Study Subjects and Control Summary
Control (n ¼ 6) Patient (n ¼ 21)
Age (SD) 61 (15) 56 (19)
Age range 46–76 19–94
Sex, n (%)
Male 4 (67) 14 (67)
Female 2 (33) 7 (33)
Procedure, n (%)
PKP 6 (100) 17 (81)
DALK 0 (0) 4 (19)
Neovascularization, n (%)
Absent 6 (100) 8 (38)
Present 0 (0) 13 (62)
Scarring, n (%)
Absent 6 (100) 4 (19)
Mild 0 (0) 5 (24)
Dense 0 (0) 12 (57)
History of prior graft, n (%)
Yes N/A 11 (52)
No N/A 10 (48)
Age, sex and procedure information for controls and patients.
Summary of clinical characteristics of neovascularization, scarring, and
history of prior graft for controls and patients. N/A, not applicable.
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these patients (Fig. 6C). We confirmed the overexpression of
MMP2, MMP8, MMP12, and MMP13 in neovascularized corneas
of patients with chronic inflammation. Taken together, these
results demonstrate that corneas with neovascularization have
upregulated expression of MMP1, MMP2, MMP8, MMP12, and
MMP13.
MMPs are expressed by neutrophils (MMPs 1, 8, 9, and 10)
and macrophages (MMPs 1, 2, 3, 7, 8, 9, 10, 12, and 13) and
can be blood-borne. If vascularization constitutes a confound-
ing variable by causing an artefactual increase in MMP level,
then it would be expected that patient samples with
neovascularization should consistently have higher levels of
MMP expression compared with patient samples lacking
neovascularization. Our results did not find this to always be
the case. Patients 12 and 13 had neovascularization but
showed low levels of MMPs (Table 2; Fig. 1). Conversely,
patients 21 and 25 did not have neovascularization, but patient
21 had a high level of MMP12 expression, and patient 25 had a
high level of MMP8 expression (Table 2; Fig. 1).
MMP Expression and Corneal Fibrosis
MMP overexpression has been linked to fibrosis in various
organs and tissues.14,39,40 Patient corneas were grouped based
on the level of scarring (dense, mild, or no scarring). MMP
expression levels were compared among these three groups
and the control corneas (Fig. 7A). MMP1 (P¼0.03), MMP2 (P¼
0.005), MMP8 (P¼ 0.01), MMP12 (P¼ 0.0008), and MMP13 (P
¼ 0.0004) were significantly overexpressed in corneas with
dense scarring when compared to controls. MMP2 (P¼ 0.03),
MMP3 (P¼ 0.009), MMP12 (P¼ 0.004), and MMP13 (P¼ 0.04)
were significantly more expressed in corneas with dense
scarring compared with corneas with mild scarring (Fig. 7B).
MMP12 levels were higher in corneas with no scarring
compared to controls (P ¼ 0.009) or in corneas with dense
scarring compared to corneas with mild scarring (P ¼ 0.01).
These observations held true when we performed a subanal-
ysis excluding patients showing signs of acute inflammation
(patients 8 and 16) (Fig. 7C). These results show that MMP1,
MMP2, MMP8, MMP12, and MMP13 expression was positively
associated with the increased levels of corneal fibrosis.
MMP Expression and Keratoconus
Altered expression of several MMPs has been associated with
keratoconus.41,42 We, therefore, compared MMP expression
levels of keratoconic corneas to controls and nonkeratoconic
corneas (Fig. 8A). MMP1 (P¼ 0.03), MMP2 (P¼ 0.005), MMP8
(P ¼ 0.006), MMP12 (P ¼ 0.0002), and MMP13 (P ¼ 0.0006)
were significantly overexpressed in nonkeratoconic diseased
corneas when compared to controls (Fig. 8B); MMP2 (P ¼
0.002), MMP8 (P ¼ 0.02), and MMP12 (P ¼ 0.0007) were also
FIGURE 1. Expression levels of individual MMPs in control and diseased cornea samples. Individual MMP levels (pg/mg of total protein) in corneal
analytes were measured by Luminex assay. Patients 1 to 6 are control corneas, and patients 7 to 27 are diseased patient corneas as described in Table
2.
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overexpressed in nonkeratoconic diseased corneas when
compared to keratoconic corneas. Interestingly, MMP3 levels
were significantly lower in keratoconic corneas compared to
both control (P ¼ 0.04) and nonkeratoconic diseased corneas
(P ¼ 0.0003). Taken together, these results show that
keratoconus corneas do not overexpress MMPs and, in fact,
have reduced MMP3 expression.
DISCUSSION
Luminex bead-based assays are highly sensitive and are
increasingly used for biomarker discovery and detection in
clinical samples.43 In this study, we used the Luminex
technology to demonstrate the overexpression of several
MMPs (MMPs 2, 8, 12, and 13) in corneas from patients
requiring keratoplasty. Although mouse corneas have been
used previously,44,45 to our knowledge this is the first time
human corneas were used in a Luminex-based assay to
simultaneously ascertain the expression of multiple MMPs.
Although MMPs were expressed at a basal level in control
samples, patient corneas displayed a wide range of individual
MMP expression. In particular, higher expression levels of
MMPs 1, 2, 8, 12, and 13 were observed in corneas with
neovascularization and fibrosis, indicating a critical role of
these MMPs in these repair processes. These findings are
consistent with studies linking MMP expression levels and
severity of corneal disease.46,47
Corneal fibrosis takes weeks to months to develop, and
corneal transplantation is typically postponed until the level of
fibrosis has stabilized to reduce the risk of potential graft
rejection that is more likely occur with active corneal
inflammation. Consistent with this clinical protocol, only 2 of
the 21 diseased corneal samples had evidence of active
inflammation, whereas the majority of patient samples had
chronic stable disease. Despite the cessation of the active
pathologic process, and likely resolution of associated chronic
inflammation, our results demonstrate that specific MMPs
(MMPs 1, 2, 8, 12, and 13) can still be expressed in clinically
inactive disease.
The observation of MMP12 overexpression in human
corneas is novel. MMP12 has been shown to be protective
against neovascularization and fibrosis while promoting repair
in a corneal wound healing mouse model,34,48 but its role in
human corneal repair remains uncertain. In this study, the
FIGURE 2. MMP expression levels in control and diseased corneas. (A) Protein expression levels (means 6 SEM) of individual MMPs in control and
patient corneas. (B) Summary of MMP expression levels (means) and Wilcoxon rank sum analysis: *P < 0.05, **P < 0.005, ***P < 0.001.
MMP Overexpression in Corneas Requiring Keratoplasty IOVS j April 2019 j Vol. 60 j No. 5 j 1739
observed overexpression of MMP12 noted in corneas with high
levels of fibrosis and neovascularization was surprising. It is
possible that the proangiogenic effects of MMPs 1, 2, 8, and 13
offset the antiangiogenic effect of MMP12. Further studies are
needed to elucidate the underlying mechanisms that may
explain this result.
MMPs have long been described as destructive during ECM
remodeling but they may have individual roles in different
physiologic pathways.49 MMP protective roles have been
described in different tissues and have been extensively
characterized in various disease models, including cancer50,51
and spinal cord injury.52,53 Because individual MMPs may have
opposite and subtle effects in repair processes, broad-spectrum
MMP inhibitors have done poorly in clinical trials,54,55
suggesting a rationale for further study of specifically targeted
inhibitors or enhancers of MMP expression.
Although other studies have described enhanced MMP9
expression in diseased corneas,56–58 we only detected MMP9
expression in two patient samples in our assay. This finding
was unexpected because activated macrophages have been
shown to induce corneal neovascularization through the
expression of MMP9 and VEGF in macrophages in a rat corneal
neovascular assay.36 Our low detection of MMP9 may be due to
technical issues with this specific analyte, although all internal
controls were within detection range. Another explanation
may be that the majority of patients had chronic, inactive
disease resulting in the samples having low levels of active
inflammation and, therefore, undetectable levels of MMP9.
Consistent with this possibility is that patient 8 had high MMP9
expression and this patient had acute inflammation from a
recent Salleras procedure.
We did not observe any influence of sex on MMP
expression. By using 50 as a cutoff, we found that only
MMP12 was slightly overexpressed in corneas of older patients.
Most patients under the age of 50 had keratoconus, and none
of them had detectable MMP12 expression. Whether this
finding is significant or the result of a bias in the enrolled
patients will be addressed in further studies. Additionally, using
age as a continuous variable, we identified a significant
correlation between MMP2 and MMP3 expression and age.
Interestingly, we measured an elevated level of MMP3
expression in corneas of patients undergoing a regraft when
compared to corneas of patients receiving a primary graft. We
also demonstrated that patients with keratoconus had reduced
levels of MMP3 when compared to both controls and patients
without keratoconus. This result is consistent with a recent
keratoconus corneal proteome study that found decreased
levels of MMP3 in diseased tissue.21 MMP3 is a secretory
FIGURE 3. Comparison of MMP expression levels in corneas according to patient sex. (A) Protein expression levels (means 6 SEM) of individual
MMPs in corneas from female and male subjects. (B) Summary of MMP expression levels (means) and Wilcoxon rank sum analysis.
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FIGURE 4. Comparison of MMP expression levels and patient age. (A) Comparison of MMP expression levels (means 6 SEM) in corneas from
patients >50 years old and <50 years old. (B) Summary of MMP expression levels (means) and Wilcoxon rank sum analysis: *P < 0.05. (C) Spearman
correlation coefficients with bootstrapped 95% confidence intervals for each MMP using age as a continuous variable: *P < 0.05.
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enzyme with a broad substrate range.59,60 Similar to MMP12,61
MMP3 not only acts as a protease but also functions as a
transcription factor and mediates tumor progression and
arthritis-related tissue remodeling.62,63 In different models
and tissues, MMP3 overexpression has been linked to
antiapoptotic effects,64 tumor progression,65 and neurodegen-
erative diseases.66 In the eye, MMP3 expression is reduced in
the aqueous humor of glaucoma patients.67 Interestingly,
MMP3 is involved in corneal epithelial cell migration during
wound healing.68,69 Our findings support further mechanistic
studies of the role of MMP3 in corneal pathophysiology and
make MMP3 an exciting potential target in patients with
keratoconus or in situations of graft rejection.
We measured overexpression of MMP2, 3, 8, and 12 in
patients without keratoconus when compared to patients with
the disease and overexpression of MMP1, 2, 8, 12, and 13 in
patients without keratoconus versus controls. Although MMPs
have been suspected to have a role in keratoconus develop-
ment,70 these findings are consistent with earlier studies
suggesting that keratoconus is associated with limited inflam-
mation and the finding of generally normal MMP levels in
keratoconic corneas.41 Other groups described mild differen-
tial patterns of MMP expression in keratoconic corneas that we
did not detect in our assay, such as slight MMP1 and MMP13
overexpression and MMP8 repression.28,71
One limitation of our study is the absence of MMP14, a key
proangiogenic MMP, in our Luminex panel. MMP14 overex-
pression has been linked to keratoconus29,41 and is associated
with several molecular mechanisms regulating neovasculariza-
tion in the cornea following injury.72 Entire collected patient
corneal samples were used to generate the corneal lysates for
the Luminex assay, so we were unable to confirm the presence
of MMP14 or the absence of MMP9 by using additional assays.
Another limitation is that the Luminex assay does not
distinguish between active and inactive MMPs. Future studies
will specifically aim at studying the expression of MMP14 and
MMP9 in the context of human diseased cornea, as well as
classical MMP activity assays, such as zymograms, by using
similarly diseased corneas to refine our findings.
Although our study is mostly descriptive, our findings in
diseased patient samples favor further mechanistic studies
focused on individual MMPs and their regulation of signaling
pathways in the context of specific corneal disease processes.
Our results support additional mechanistic analyses of MMPs 2,
8, 12, and 13 on corneal neovascularization and fibrosis
pathways and MMP3 regulation of keratoconus pathogenesis
FIGURE 5. Comparison of MMP expression levels and previous graft failure. (A) Comparison of MMP expression levels (means 6 SEM) in corneas of
patients undergoing their first corneal transplant versus corneas of patients with a history of a prior graft. (B) Summary of MMP expression levels
(means) and Wilcoxon rank sum: *P < 0.05.
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FIGURE 6. MMP expression levels in corneas with varying levels of neovascularization (NV). (A) Protein expression levels (means 6 SEM) of
individual MMPs in control corneas, patient corneas without neovascularization, and patient corneas with neovascularization. (B) Summary of MMP
expression levels (means) and Wilcoxon rank sum analysis: *P < 0.05, **P < 0.005. (C) Subanalysis of (A) excluding patients with acute corneal
inflammation (patients 8 and 16).
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FIGURE 7. MMP expression in corneas with varying levels of fibrosis. (A) Protein expression levels (means 6 SEM) of individual MMPs in control
corneas and diseased corneas with no, mild, or dense scarring. (B) Summary of MMP expression levels (means) and Wilcoxon rank sum: *P < 0.05,
**P < 0.005, ***P < 0.001. (C) Subanalysis of (A) excluding patients with acute corneal inflammation (patients 8 and 16).
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and graft rejection. Our prior studies have demonstrated the
protective effects of MMP12 on corneal neovascularization,
inflammation, and fibrosis through its effects on C-C motif
chemokine ligand 2 (CCL2), VEGFA, and plasminogen expres-
sion.34 MMPs 2, 8, and 13 have been shown to have an
opposite effect and promote corneal neovascularization and
fibrosis. A mouse model of inflammation-related corneal
neovascularization found a significant delay of neovasculariza-
tion in MMP2-deficient mice.73 MMP2 is secreted as pro-MMP2
in a complex with tissue inhibitor of metalloproteinase-2.
MMP14 cleaves pro-MMP2 and releases activated MMP2, and
the intercellular transfer of MMP14 and MMP2 between
corneal fibroblasts and endothelial cells may occur during
angiogenesis and other biological processes.74 The anti-
inflammatory effects of dexamethasone have been shown to
be mediated through MMP8 via decreased IL-1b and chemo-
kine (C-X-C motif) ligand 1 (CXCL1) expression in a
concomitant dry eye and corneal alkali burn murine model.75
Corneal keratocytes express MMP13 through the induction of
VEGFc and VEGFr3 and directly degrade type I collagen to
create spaces convenient for neovessel growth.35 Notably,
expression of tissue inhibitors of matrix metalloproteinases
(TIMPS) and extracellular matrix metalloproteinase inducer
(EMMPRIN) have been associated with MMP expression
inhibition76 and induction,77 respectively. From a therapeutic
viewpoint, understanding the pathways leading to MMP
expression and regulating neovascularization and fibrosis is
critical to the identification of novel targets.
In summary, our study has identified individual MMPs that
are upregulated in diseased human corneas and whose
increased expression corresponds to higher clinical levels of
neovascularization and fibrosis. Further mechanistic analysis of
the specific roles of these individual MMPs in various corneal
diseases, as well as the development of noninvasive methods
for measuring MMP levels in vivo, will be critical to improving
our understanding of the role of MMPs in the pathophysiology
of specific corneal diseases and for identifying potential
therapeutic targets.
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